FBXO22 is a potential therapeutic target for recurrent chondrosarcoma

Baoquan Xin,Hui Chen,Zhi Zhu,Qiujing Guan,Guangjian Bai,Cheng Yang,WeiWei Zou,Xin Gao,Lei Li,Tielong Liu
DOI: https://doi.org/10.1016/j.jbo.2024.100605
2024-05-01
Abstract:Chondrosarcoma (CHS) is a malignant bone tumor with insensitivity to both radiotherapy and chemotherapy, and a high recurrence rate. However, the latent mechanism of recurrent CHS (Re-CHS) remains elusive. Here, we discovered that FBXO22 was highly expressed in clinical samples of Re-CHS. FBXO22 played a significant role in various cancers. However, the role of FBXO22 in Re-CHS remained unclear. Our research demonstrated that suppressing FBXO22 abated the proliferation and migration of CHS cells and facilitated their apoptosis. In addition, suppressing FBXO22 raised the expression of PD-L1 in Re-CHS. All these findings provide new evidence for using FBXO22 and PD-L1 as combined targets to prevent and treat Re-CHS, which may prove to be a novel strategy for immunotherapy of CHS, especially Re-CHS.
What problem does this paper attempt to address?